Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.115676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Alan M Elder und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Cancer Bio…. Hauptthemen laut MEDLINE: Semaphorins, B7-H1 Antigen, Breast Neoplasms, Antigens, CD. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Postpartum mammary gland remodeling after a pregnancy/lactation cycle is characterized by mechanisms of cell death and inflammation. Here, we show that SEMA7A promotes PD-L1 expression in immune cells of the mammary tissue during involution. These same phenotypes are mimicked in the microenvironment of SEMA7A-expressing tumors, which partially respond to αPD-1/αPD-L1 treatments in vivo. However, cells that remain after treatment are enriched for SEMA7A expression. Therefore, we tested a monoclonal antibody that directly targets SEMA7A-expressing tumors, in part, by reducing SEMA7A-mediated upregulation of PD-L1. In vivo, the SEMA7A monoclonal antibody reduces tumor growth and/or promotes complete regression of mouse mammary tumors, reduces some immunosuppressive phenotypes in the tumor microenvironment, and restores cytotoxic T cells, suggesting that SEMA7A may be a candidate for immune-based therapy for breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Cancer Biology Graduate Training Program, University of Colorado Anschutz Medica…
- Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- University of Colorado Cancer Center, Aurora, CO, USA; Department of Immunology and Microbiology, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- University of Colorado Cancer Center, Aurora, CO, USA.
- Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; University of Colorado Cancer Center, Aurora, CO, USA; Young Women's Breast Canc…
Förderung
- NCI NIH HHS
- NCATS NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- NICHD NIH HHS
- NIAMS NIH HHS
- National Institute of Child Health and Human Development
- American Cancer Society
Zitieren
APA
Elder, A. M., Fairchild, H. R., Kines, K. T., Cozzens, L. M., Becks, A. R., Slansky, J. E., Anderson, S. M., & Lyons, T. R. (2025). Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. Cell Reports. https://doi.org/10.1016/j.celrep.2025.115676
Vancouver
Elder AM, Fairchild HR, Kines KT, Cozzens LM, Becks AR, Slansky JE, et al. Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer. Cell Reports. 2025. doi:10.1016/j.celrep.2025.115676
BibTeX
@article{Elder2025,
author = {Elder, Alan M and Fairchild, Heather R and Kines, Kelsey T and Cozzens, Lauren M and Becks, Alexandria R and Slansky, Jill E and Anderson, Steven M and Lyons, Traci R},
title = {Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.115676}
}
EUVIMED